Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?

Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you. Shares of Structure Therapeutics (GPCR -0.30%) shot up more than 50% during the first week of June. The stock market is responding to a positive readout for an experimental weight-management drug the company is working on. Structure Therapeutics is a clinical-stage drugmaker developing an orally available therapy, called GSBR-1290. Structure's lead candidate works like semaglutide, the ...